Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
50.22
-4.48 (-8.19%)
At close: Nov 15, 2024, 4:00 PM
50.14
-0.08 (-0.16%)
After-hours: Nov 15, 2024, 5:59 PM EST
Cytokinetics Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Cytokinetics stock have an average target of 83.67, with a low estimate of 60 and a high estimate of 120. The average target predicts an increase of 66.61% from the current stock price of 50.22.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock from 16 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 5 | 5 |
| Buy | 7 | 7 | 7 | 6 | 6 | 7 |
| Hold | 3 | 3 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 15 | 15 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $120 | Strong Buy | Reiterates | $120 | +138.95% | Nov 11, 2024 |
| RBC Capital | RBC Capital | Buy Initiates $80 | Buy | Initiates | $80 | +59.30% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $120 | Strong Buy | Reiterates | $120 | +138.95% | Nov 7, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Oct 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $120 | Strong Buy | Reiterates | $120 | +138.95% | Oct 17, 2024 |
Financial Forecast
Revenue This Year
6.55M
from 7.53M
Decreased by -12.99%
Revenue Next Year
66.27M
from 6.55M
Increased by 911.39%
EPS This Year
-5.37
from -5.45
EPS Next Year
-5.33
from -5.37
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 44.2M | 237.2M | 578.5M | ||
| Avg | 6.6M | 66.3M | 351.5M | ||
| Low | 1.1M | 15.7M | 200.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 487.2% | 3,520.3% | 772.9% | ||
| Avg | -13.0% | 911.4% | 430.4% | ||
| Low | -85.7% | 139.3% | 202.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -5.17 | -3.68 | -1.52 | ||
| Avg | -5.37 | -5.33 | -3.65 | ||
| Low | -5.48 | -6.58 | -5.67 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.